Data Science Funding Announcements & Notices
Data science and informatics funding announcements and notices are available from NCI and NIH programs. Browse below for opportunities, requests for information, notices, and initiatives.
| Title Sort descending | FOA | Organization | Release Date | Expire Date | Purpose |
|---|---|---|---|---|---|
| Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) | PAR-23-025 | NIAMS | Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed) | ||
| Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) | PAR-23-026 | NIAMS | Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed) | ||
| Animal and Biological Material Resource Centers (P40) (Clinical Trials Not-Allowed) | RFA-OD-23-001 | ORIP | This FOA encourages grant applications for Animal and Biological Material Resource Centers. These Centers provide support for special colonies of laboratory animals, as well as other resources such… More | ||
| Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed) | PAR-23-264 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of small molecules that function to elucidate the biology of disease as… More | ||
| Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed) | PAR-23-168 | NIMH | The objective of this funding opportunity announcement (FOA) is to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment… More | ||
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) | PAR-23-313 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to support the validation of molecular/cellular/imaging markers (referred to as "… More | ||
| Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) | PAR-23-314 | NCI | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to accelerate the adoption and validation of molecular/cellular/imaging markers (referred to as "… More | ||
| Assessment of Climate at Institutions (ACt) Award (RC2 - Clinical Trial Not Allowed) | PAR-24-038 | NIDCR | The objective of this Notice of Funding Opportunity (NOFO) is to solicit applications to conduct institutional climate assessments using validated survey instruments and to develop action plans for… More | ||
| Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) | RFA-DA-24-007 | NIDA | oThe goal of this FOA is to attract outstanding early-stage investigators to the field of chemistry and pharmacology of substance used disorders. The award will support those in an early stage of… More | ||
| Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) | PAR-23-021 | NIDA | Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of… More |